InspireMD Q1 net loss widens to $0.22/sh; FDA approval of CGuard Prime expected Q3 2025

InspireMD, Inc.

2025-Q1 EPS reported -$0.22 revenue$1,529,000

Revenue $1.529M (+1.2% YoY); net loss $11.166M ($0.22/sh) vs $7.032M loss ($0.21/sh) in Q1 2024.
Operating expenses rose 52.5% to $11.752M on U.S. sales force build and CGuard Prime launch preparation.
Cash and securities $26.086M at March 31, down from $34.637M at Dec 31, 2024.
FDA PMA for CGuard Prime carotid stent system anticipated in Q3 2025; commercial team in place.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.